Segment, Geographic and Other Revenue Information (Tables)

3 Months Ended

Mar. 30, 2025

Schedule of Segment Reporting Information by Segment


The following provides selected information by reportable segment:
	Three Months Ended
	Total Revenues				Earnings(a)				Depreciation and Amortization(b)
(MILLIONS)	March 30, 2025		March 31, 2024		March 30, 2025		March 31, 2024		March 30, 2025		March 31, 2024
Reportable Segment:
Biopharma(c)	$	13,441	$	14,604	$	7,105	$	7,622	$	331	$	337
Other business activities(d)	273		275		(1,420)		(2,007)		74		86
Reconciling Items:
Amortization of intangible assets					(1,211)		(1,308)		1,211		1,308
Acquisition-related items					(282)		(508)		(1)		1
Certain significant items(e)					(1,407)		(378)		4		4
	$	13,715	$	14,879	$	2,785	$	3,421	$	1,618	$	1,736

(a)Income from continuing operations before provision/(benefit) for taxes on income.

(b)Certain production facilities are shared. Depreciation is allocated based on estimates of physical production.

(c)Biopharma’s earnings in the first quarter of 2025 reflect a credit to Cost of sales representing a favorable revision of our estimate of accrued royalties. Biopharma’s revenues and earnings in the first quarter of 2024 reflected a non-cash favorable product return adjustment of $771 million (see Note 17C in our 2024 Form 10-K). Biopharma’s earnings also include dividend income from our investment in ViiV of $39 million in the first quarter of 2025 and $61 million in the first quarter of 2024 recorded in Other (income)/deductions––net.

(d)Other business activities include revenues and costs associated with PC1 and Pfizer Ignite as well as costs that we do not allocate to our operating segments, per above.

(e)Earnings in the first quarter of 2025 include, among other items restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $666 million (primarily recorded in Restructuring charges and certain acquisition-related costs). See Note 3.


The following provides Biopharma reportable segment information regularly provided to the CODM:
	Three Months Ended
(MILLIONS)	March 30, 2025		March 31, 2024
Biopharma reportable segment:
Biopharma total revenues	$	13,441	$	14,604
Less:
Cost of sales	2,314		2,643
Selling, informational and administrative expenses	2,150		2,334
Research and development expenses	1,941		2,151
Acquired in-process research and development expenses	9		—
Other (income)/deductions––net	(78)		(148)
Biopharma earnings	$	7,105	$	7,622

Schedule of Revenues by Geographic Region


The following summarizes revenues by geographic area:
	Three Months Ended
(MILLIONS)	March 30, 2025		March 31, 2024
United States	$	8,374	$	9,514
International:
Developed Markets	3,178		3,198
Emerging Markets	2,163		2,167
Total revenues	$	13,715	$	14,879

Schedule of Significant Product Revenues

The following provides detailed revenue information for several of our major products:


(MILLIONS)		Three Months Ended
PRODUCT	PRIMARY INDICATION OR CLASS	March 30, 2025		March 31, 2024
TOTAL REVENUES		$	13,715	$	14,879
GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)		$	13,441	$	14,604
Primary Care		$	5,696	$	7,211
Eliquis(a)	Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism	1,923		2,040
Prevnar family	Active immunization to prevent pneumonia, invasive disease and otitis media caused by Streptococcus pneumoniae	1,660		1,691
Comirnaty	Active immunization to prevent COVID-19	565		354
Paxlovid(b)	COVID-19 in certain high-risk patients	491		2,035
Nurtec ODT/Vydura	Acute treatment of migraine and prevention of episodic migraine	248		178
Abrysvo	Active immunization to prevent RSV infection	131		145
All other Primary Care	Various	677		770
Specialty Care		$	3,987	$	3,843
Vyndaqel family	ATTR-CM and polyneuropathy	1,486		1,137
Sulperazon (Outside the U.S. and Canada)	Bacterial infections	164		167
Zithromax	Bacterial infections	158		200
Inflectra	Crohn’s disease, pediatric Crohn’s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis	153		158
Enbrel (Outside the U.S. and Canada)	RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis	140		159


(MILLIONS)		Three Months Ended
PRODUCT	PRIMARY INDICATION OR CLASS	March 30, 2025		March 31, 2024
Zavicefta (Outside the U.S. and Canada)	Bacterial infections	135		125
Xeljanz	RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis, ankylosing spondylitis	128		194
Cibinqo	Atopic dermatitis	58		42
All other Hospital	Various	1,155		1,149
All other Specialty Care	Various	409		513
Oncology		$	3,758	$	3,549
Ibrance	HR-positive/HER2-negative metastatic breast cancer	977		1,054
Xtandi(c)	mCRPC, nmCRPC, mCSPC, nmCSPC	458		418
Padcev	Locally advanced or metastatic urothelial cancer	426		341
Oncology biosimilars(d)	Various	264		264
Lorbrena	ALK-positive metastatic NSCLC	222		164
Inlyta	Advanced renal cell carcinoma	219		237
Adcetris	Hodgkin lymphoma and certain T-cell lymphomas	218		257
Bosulif	Philadelphia chromosome–positive chronic myelogenous leukemia	151		145
Braftovi/Mektovi	Metastatic melanoma in patients with a BRAFV600E/K mutation and for metastatic NSCLC in patients with a BRAFV600E mutation; and, for Braftovi for the treatment of BRAFV600E-mutant mCRC, in combination with Erbitux® (cetuximab)(e) (after prior therapy) or cetuximab and mFOLFOX6	136		116
Aromasin	Post-menopausal early and advanced breast cancer	108		82
Tukysa	Unresectable or metastatic HER2-positive breast cancer; RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer	102		106
Elrexfio	Relapsed or refractory multiple myeloma	60		13
Talzenna	Treatment of BRCA gene-mutated, HER2-negative, inoperable or recurrent breast cancer; and, in combination with Xtandi (enzalutamide), of adult patients with HRR gene-mutated mCRPC	40		23
Tivdak	Recurrent or mCC	33		28
All other Oncology	Various	345		301
PFIZER CENTREONE(f)		$	257	$	258
PFIZER IGNITE		$	17	$	17

BIOPHARMA		$	13,441	$	14,604
PFIZER U.S. COMMERCIAL DIVISION(g)		8,285		9,426
PFIZER INTERNATIONAL COMMERCIAL DIVISION		5,156		5,178

Total Alliance revenues included above		$	2,113	$	2,172
Total Royalty revenues included above		$	308	$	263

(a)Reflects Alliance revenues and product revenues.

(b)The amount for 2024 included a $771 million favorable final adjustment to the estimated non-cash revenue reversal of $3.5 billion recorded in the fourth quarter of 2023, reflecting 5.1 million EUA-labeled treatment courses returned by the U.S. government through February 29, 2024 versus the estimated 6.5 million treatment courses that were expected to be returned as of December 31, 2023.

(c)Primarily reflects Alliance revenues and royalty revenues.

(d)Biosimilars are highly similar versions of approved and authorized biological medicines. Oncology biosimilars primarily include Ruxience, Retacrit, Trazimera, Zirabev and Nivestym.

(e)Erbitux® is a registered trademark of ImClone LLC.

(f)PC1 includes revenues from our contract manufacturing and our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with legacy Pfizer businesses/partnerships.

(g)Refer to Note 13A above.